Navigation Links
Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
Date:5/14/2008

SCHAUMBURG, Ill., May 14 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it will contribute US$20,000 to the American Red Cross to assist the victims of Monday's earthquake in central China.

"As a part of the global community, we were saddened by the devastation experienced by the people of the Sichuan province," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "We hope our contribution to the recovery efforts there will help in some small way ease the burden for the Sichuan residents."

The earthquake's epicenter was 55 miles from Chengdu, Sichuan Province's capital with a population of 12 million people. In conjunction with its local joint venture partners, Chengdu Great Southwest Pharmaceutical Co., Ltd., Sagent is presently constructing an FDA-compliant, sterile, injectable, finished product manufacturing facility in Chengdu.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
4. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
8. Medimetriks Pharmaceuticals, Inc. Begins Operations
9. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Two New Appointments at Meditor Pharmaceuticals Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...
(Date:12/16/2009)... Eppendorf has initiated an,import ban for Nanosphere, ... of European patent EP 1 179 180 ... quantification of a target compound". The import,ban ... respective products into any country of,the European ... any,violating products. , ...
(Date:12/15/2009)... one of three Department of Energy (DOE) bio-energy research ... protect its valuable intellectual property. , ... ... 2009 -- Surety, LLC , the leading provider ... that the Joint BioEnergy Institute (JBEI), one of three ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 Aethlon Medical, ... that Dr. Jeff Schorey and Dr. Wayne Comper ... of Exosome Sciences, Inc. (ESI). Both Dr. Schorey ... exosome field. ESI, a wholly owned subsidiary of ... discovery that the Hemopurifier®, a medical device being ...
Breaking Biology Technology:Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
... BEIJING, March 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE ... of vaccines in,China, announced today that the Chinese ... of China, the Ministry of Finance and the ... subsidiary,Sinovac Biotech Co. Ltd.(Sinovac Beijing), high-tech enterprise status.,According ...
... Spectral Diagnostics Inc. (TSX:SDI) today announced that it ... Inc. of Japan granting Spectral the exclusive development ... a therapeutic device for the treatment of sepsis ... terms of the agreement, Spectral will seek FDA ...
... March 9 MannKind Corporation (Nasdaq: MNKD ... with Pfizer Inc. (NYSE: PFE ) to ... Main, Germany and assets related to the production of ... production equipment, a quantity of bulk insulin and a ...
Other Biology Technology:Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 2Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 3Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market 2Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4
(Date:12/15/2009)... at VIB and Ghent University in Flanders, Belgium have ... shock, the major cause of death in intensive care ... gas in mice with septic shock, researchers Anje Cauwels ... much less damage, while their chances of survival increased ... generally assumed that nitric oxide is responsible for the ...
(Date:12/15/2009)... 2006, a team of Spanish and American researchers found the ... Bonares, Huelva. Now they have published, for the first time, ... with the death of the young cetacean, possibly a baleen ... first discovery of the partial fossil remains of a whale ... Huelva Sands sedimentary formation, but it is the first time ...
(Date:12/15/2009)... and economic toll on society. It is estimated that ... in U.S. waters and it,s likely that rip currents account ... disconnect exists between rip current research and public understanding. ... and more importantly, most people do not know how to ... The goal of the Rip Current Symposium is to identify ...
Breaking Biology News(10 mins):Septic shock: Nitric oxide beneficial after all 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3Lumetra Announces Sale of Subsidiary IntegriGuard 58553 1Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 1Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 2Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 3Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 4Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 5Blue Belt Technologies Inc Closes Series A Financing 5111 1Blue Belt Technologies Inc Closes Series A Financing 5111 2Blue Belt Technologies Inc Closes Series A Financing 5111 3
... features of a living organism. An external or internal ... genes whose activity turns on or off various biological ... repair, cellular suicide etc). Many of the regulatory functions ... to 6 - 10 nucleotide long binding sequences located ...
... Capuchin monkeys are playful, inquisitive primates known for ... New research now shows that just like humans, ... of the brain, specifically in the corpus callosum, the ... , A recently published paper by Associate Professor of ...
... of world population is infected with hepatitis C virus (HCV). ... chronic hepatitis, and many of the chronic infections will develop ... cure for chronic hepatitis C, nor is there any approved ... health problem worldwide. , Twenty to fifty percent of HCV ...
Other Biology News:Gene regulation in humans is closer than expected to simple organisms 2Influence of sex and handedness on brain is similar in capuchin monkeys and humans 2Who will recover spontaneously from hepatitis C virus infection 2
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
Biology Products: